Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VRDN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsViridian eliminates all debt with $55.1M prepayment to Hercules Capital
Filed May 28, 2026 · Period ending May 27, 2026 · ~1 min read
Key Changes
-
high
Viridian paid $55.1M on May 27 to fully terminate its Hercules Capital loan facility, eliminating all debt obligations, covenants, and future interest payments. The company is now debt-free.
Item 1.01 view on EDGAR → -
medium
The terminated loan carried a high interest rate of 8.95-9.45% annually on $50M borrowed from a up to $300M facility, representing significant financing costs now avoided.
Item 1.01 view on EDGAR → -
medium
The prepayment eliminates interest-only payments through 2029-2030 and subsequent principal payments until the October 2030 maturity date, improving cash flow predictability.
Item 1.01 view on EDGAR →
Summary
Viridian Therapeutics voluntarily prepaid its entire debt facility with Hercules Capital, paying approximately $55.1 million to terminate a loan agreement originally established in April 2022. The company had borrowed $50 million from a up to $300 million maximum facility at interest rates ranging from 8.95% to 9.45% annually.
By eliminating this debt, Viridian strengthens its balance sheet and removes ongoing debt service obligations that would have extended through October 2030. For retail investors, this move signals financial strength—the company has sufficient cash to retire expensive debt early rather than maintaining leverage.
The elimination of high-interest debt (nearly 9-9.5%) should improve future profitability by reducing interest expense. The key question going forward is how Viridian will deploy its remaining cash: whether toward clinical development, business development activities, or maintaining a stronger cash position for operational flexibility. Watch upcoming quarterly filings to assess cash burn rate and runway without the debt cushion.
Section-by-Section Diff
Event · Item 1.02 — Termination of a Material Definitive Agreement
Item 1.02 — Termination of a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 27, 2026, Viridian Therapeutics, Inc. (the “Company”) completed a voluntary prepayment of all outstanding principal, accrued and unpaid interest, fees, costs and expenses, equal to approximately $55.1 million in the aggregate (the “Payoff Amount”), under the Loan and Security Agreement, entered into and effective as of April 1, 2022, by and among the Company, certain of its subsidiaries from time to time party thereto, Hercules Capital, Inc. (“Hercules”) and certain other lenders named therein, which was subsequently amended on August 7, 2023 and October 17, 2025 (as amended, the “Loan Agreement”). Upon receipt by Hercules of the Payoff Amount on May 27, 2026, all obligations, covenants, debts and liabilities of the Company under the Loan Agreement were satisfied and discharged in full, and the Loan Agreement and all other documents entered into in connection with the Loan Agreement were terminated.
Viridian voluntarily prepaid approximately $55.1 million to Hercules Capital, fully satisfying and terminating its loan agreement originally entered in April 2022. This eliminates all debt obligations, covenants, and liabilities under the facility, strengthening the company's balance sheet by removing debt service requirements.
Added in current filing · verify on EDGAR →
The Loan Agreement provided for a term loan with aggregate maximum borrowings of up to $300 million (the “Term Loan”). Under the Loan Agreement, the Company borrowed $50 million. The Term Loan bore interest at a floating per annum rate equal to the greater of 8.95% and 1.45% above the Prime Rate (as defined in the Loan Agreement), provided that the interest rate did not exceed a per annum rate of 9.45%.
The terminated loan facility had a $300 million maximum capacity, of which Viridian borrowed $50 million. The interest rate was floating at the greater of 8.95% or Prime plus 1.45%, capped at 9.45% annually, representing a relatively high cost of debt that the company has now eliminated.
Added in current filing · verify on EDGAR →
Interest-only payments on the borrowings under the Loan Agreement were due through October 1, 2029, or if certain regulatory milestones were met, through October 1, 2030. After the interest-only payment period, borrowings under the Loan Agreement were due in equal monthly payments of principal and accrued interest until the maturity date of October 1, 2030.
The loan originally required only interest payments through October 2029 (or 2030 if milestones were met), followed by principal and interest payments until maturity in October 2030. By prepaying now, Viridian avoids these future obligations and interest costs over the remaining term.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 28, 2026 · How we verify